🇺🇸 FDA
Patent

US 12251403

Genetically engineered hematopoietic stem cells and uses thereof

granted A61KA61K2035/124A61K2039/505

Quick answer

US patent 12251403 (Genetically engineered hematopoietic stem cells and uses thereof) held by Vor Biopharma Inc. expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vor Biopharma Inc.
Grant date
Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2035/124, A61K2039/505, A61K2239/48, A61K35/28